Appropriateness of Age Thresholds for Palivizumab Prophylaxis in Preterm Infants

被引：0
|
作者：
Knox, Caitlin A. [1 ]
Hampp, Christian [1 ]
Kubilis, Paul S. [1 ]
Linden, Stephan [1 ]
Winterstein, Almut G. [1 ]
机构：
[1] Univ Florida, Gainesville, FL USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2011年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
578
引用
收藏
页码：S252 / S252
页数：1
相关论文
共 50 条
  • [1] Palivizumab prophylaxis in preterm infants
    Tang, Paul Kiet
    [J]. LANCET RESPIRATORY MEDICINE, 2017, 5 (03): : 171 - 171
  • [2] Precise Gestational Age Definitions Needed for Palivizumab Prophylaxis in Preterm Infants
    Chabra, Shilpi
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197 (05) : 680 - 680
  • [3] Effect of Palivizumab Prophylaxis on Subsequent Recurrent Wheezing in Preterm Infants
    Yoshihara, Shigemi
    Kusuda, Satoshi
    Mochizuki, Hiroyuki
    Okada, Kenji
    Nishima, Sankei
    Simoes, Eric A. F.
    [J]. PEDIATRICS, 2013, 132 (05) : 811 - 818
  • [4] Appropriateness of Age Thresholds for Respiratory Syncytial Virus Immunoprophylaxis in Moderate-Preterm Infants A Cohort Study
    Winterstein, Almut G.
    Knox, Caitlin A.
    Kubilis, Paul
    Hampp, Christian
    [J]. JAMA PEDIATRICS, 2013, 167 (12) : 1118 - 1124
  • [5] PALIVIZUMAB PROPHYLAXIS FOR VRS INFECTION IN PRETERM INFANTS WITH GESTATIONAL AGE ≤30 WEEKS: COMPLIANCE, EFFICACY AND ADVERSE EVENTS
    Serrao, F.
    Gallini, F.
    Cota, F.
    Maggio, L.
    Fusco, F.
    De Carolis, M. P.
    Romagnoli, C.
    [J]. PEDIATRIC RESEARCH, 2010, 68 : 437 - 437
  • [6] Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab
    Manini, Mariana Bueno
    Matsunaga, Natasha Yumi
    Gianfrancesco, Livea
    Oliveira, Marina Simoes
    Vieira de Carvalho, Maria Rosa
    Martins Tengler Ribeiro, Gisleine Leila
    Morais, Eliane de Oliveira
    Ribeiro, Maria Angela Goncalves O.
    Morcillo, Andre Moreno
    Ribeiro, Jose Dirceu
    Dalbo Contrera Toro, Adyleia Aparecida
    [J]. JORNAL BRASILEIRO DE PNEUMOLOGIA, 2021, 47 (05)
  • [7] Hospitalization for Lower Respiratory Tract Disease in Preterm Infants: Effects of Prophylaxis with Palivizumab
    Faldella, G.
    Alessandroni, R.
    Aquilano, G.
    Vandini, S.
    Lanari, M.
    Silvestri, M.
    Pistorio, A.
    Rossi, G. A.
    [J]. JOURNAL OF CHEMOTHERAPY, 2010, 22 (01) : 30 - 35
  • [8] Palivizumab prophylaxis in 'late preterm' newborns
    Lanari, Marcello
    Silvestri, Michela
    Rossi, Giovanni A.
    [J]. JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2010, 23 : 53 - 55
  • [9] 870 Palivizumab Prophylaxis for Vrs Infection in Preterm Infants with Gestational Age ≤30 Weeks: Compliance, Efficacy and Adverse Events
    F Serrao
    F Gallini
    F Cota
    L Maggio
    F Fusco
    M P De Carolis
    C Romagnoli
    [J]. Pediatric Research, 2010, 68 : 437 - 437
  • [10] Palivizumab for preterm infants. Is it worth it?
    Embleton, ND
    Harkensee, C
    Mckean, MC
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 2005, 90 (04): : F286 - F289
12345